argenx_logo_default.png
argenx to Present at Upcoming Investor Conferences
June 01, 2022 01:00 ET | argenx SE
June 1, 2022Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today...
argenx_logo_default.png
argenx Announces the UK MHRA has Granted Early Access to Efgartigimod for Generalized Myasthenia Gravis
May 31, 2022 01:00 ET | argenx SE
        Positive scientific opinion under Early Access to Medicines Scheme (EAMS) will make efgartigimod available to eligible generalized myasthenia gravis (gMG) patients in the UK prior to marketing...
argenx_logo_default.png
argenx Announces Publication of Translational Data of Efgartigimod in Autoimmune Skin Blistering Diseases
May 19, 2022 07:00 ET | argenx SE
Translational data from Phase 2 study of efgartigimod in pemphigus further demonstrate argenx’s scientific leadership in FcRn biology, providing new insights into pathophysiology of autoimmune skin...
argenx_logo_default.png
argenx announces results of Annual General Meeting of Shareholders
May 10, 2022 17:30 ET | argenx SE
May 10, 2022 Breda, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases,...
argenx_logo_default.png
argenx Announces Positive Phase 3 Data from ADVANCE Trial of VYVGART® (efgartigimod alfa-fcab) in Adults with Primary Immune Thrombocytopenia
May 05, 2022 01:00 ET | argenx SE
Study met primary endpoint, demonstrating a higher proportion of sustained platelet response with VYVGART treatment compared to placebo (p=0.0316); responders observed across patient types...
argenx_logo_default.png
argenx Reports First Quarter 2022 Financial Results and Provides Business Update
May 05, 2022 01:00 ET | argenx SE
$21.2 million in VYVGART® (efgartigimod alfa-fcab) net product sales during initial quarter of U.S. commercial launchMet primary endpoint in Phase 3 ADVANCE trial of VYVGART for treatment of primary...
argenx_logo_default.png
argenx to Present at BofA Securities 2022 Healthcare Conference
May 04, 2022 01:00 ET | argenx SE
May 4, 2022Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today...
argenx_logo_default.png
argenx to Report First Quarter 2022 Financial Results and Business Update on May 5, 2022
April 28, 2022 01:00 ET | argenx SE
April 28, 2022Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today...
argenx_logo_default.png
argenx Presents Interim Results from ADAPT+ Open-Label Extension Study Evaluating VYVGART® (efgartigimod alfa-fcab) in Generalized Myasthenia Gravis at 2022 AAN Annual Meeting
April 05, 2022 01:00 ET | argenx SE
         Interim data suggest long-term treatment with VYVGART provides improvement in generalized myasthenia gravis (gMG) disease scores that remains consistent over multiple treatment cycles ...
argenx_logo_default.png
argenx announces full exercise of underwriters’ option to purchase additional ADSs
March 29, 2022 17:00 ET | argenx SE
Regulated information — Inside information March 29, 2022, 11:00 PM CETMarch 29, 2022, 5:00 PM ET Breda, the Netherlands — argenx SE (Euronext & Nasdaq: ARGX), a global immunology company...